Clinical Trial Update: Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo [Phase 2]

View source ↗

Summary

Phase II long-term/low-dose Xeloda (capecitabine) trial in head and neck squamous cell carcinoma after surgery and/or radiation/chemo completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Xeloda (capecitabine)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-01-19